Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025

Imatinib for pulmonary arterial hypertension was the first antiproliferative approach in this condition’s treatment and may still be relevant today despite its complicated history. Originally developed as a cancer therapy (tyrosine kinase inhibitor), it showed very good results in pulmonary arterial hypertension, creating a lot of expectation when the IMPRES study was presented at the […]

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025 Read Post »

Hoarseness as a rare symptom of idiopathic pulmonary arterial hypertension due to Ortner Syndrome, American Journal of Case Reports, March 28, 2025

The case study reported in a recent article for the American Journal of Case Reports, describes a 32-year-old male patient with idiopathic pulmonary arterial hypertension (IPAH) who presented with hoarseness. The hoarseness was attributed to Ortner syndrome, where an enlarged pulmonary artery compressed the left recurrent laryngeal nerve, causing left vocal fold paralysis. Diagnostic workup

Hoarseness as a rare symptom of idiopathic pulmonary arterial hypertension due to Ortner Syndrome, American Journal of Case Reports, March 28, 2025 Read Post »

A large-scale randomised controlled trial in Taiwan reveals that the use of an artificial intelligence-enabled electrocardiogram alert system can significantly reduce mortality in hospitalized patients, Nature Medicine

This article on the use of an artificial intelligence alert system is not new but it was mentioned during the recent European Society of Cardiology CRT – Cardiovascular Round Table – on the them of AI in cardiovascular care, which took place on March 26-27, 2025 (link) The primary clinical hypothesis of this randomised controlled

A large-scale randomised controlled trial in Taiwan reveals that the use of an artificial intelligence-enabled electrocardiogram alert system can significantly reduce mortality in hospitalized patients, Nature Medicine Read Post »

Pregnancy and pulmonary arterial hypertension: Management challenges, International Journal of Cardiology Congenital Heart Disease, March 2025

This article, published in the International Journal of Cardiology Congenital Heart Disease in March 2025, discusses pulmonary hypertension in pregnancy, historically associated with poor outcomes, and provides recent evidence suggesting that the prognosis varies based on underlying cause and severity. The authors emphasize the need for individualized care through a multidisciplinary team approach at tertiary

Pregnancy and pulmonary arterial hypertension: Management challenges, International Journal of Cardiology Congenital Heart Disease, March 2025 Read Post »

How family dynamics are affected in the case of a genetic pulmonary arterial hypertension diagnosis: interview and focus group highlights, European Respiratory Journal Open research, March 24, 2025

A study titled “Navigating family dynamics and ethical considerations in genetic diagnosis of pulmonary arterial hypertension: insights from in-depth semi-structured interviews”, published on the ERJ Open research on March 24, 2025, examines the impact of genetic diagnosis on families affected by pulmonary arterial hypertension (PAH). Researchers interviewed 63 stakeholders across 53 interviews and focus groups

How family dynamics are affected in the case of a genetic pulmonary arterial hypertension diagnosis: interview and focus group highlights, European Respiratory Journal Open research, March 24, 2025 Read Post »

Should sex differences be taken into account when conducting a risk assessment for pulmonary arterial hypertension patients? International Journal of Cardiology, March 20, 2025

In a multicenter study from the FOCUS-PAH registry (2001-2022), researchers examined sex differences among 410 pulmonary arterial hypertension patients, and found that women represented 2 out of 3 patients (66.6 %) vs 33.4%). The findings, published in the International Journal of Cardiology on March 20, 2025 in an article titled “Sex differences in pulmonary arterial

Should sex differences be taken into account when conducting a risk assessment for pulmonary arterial hypertension patients? International Journal of Cardiology, March 20, 2025 Read Post »

Advancing pulmonary hypertension care at the ERN-Lung Annual Board meeting, Paris, March 24-25, 2025

The annual Board meeting of the ERN-LUNG – European Reference Network for rare respiratory diseases, took place in Paris on March 24-25, 2025, with over 100 participants, not only from the EU but also UK, US and Canada. Two European patient representatives, Pisana Ferrari and Hall Skaara, (2nd and 3rd from left in the cover

Advancing pulmonary hypertension care at the ERN-Lung Annual Board meeting, Paris, March 24-25, 2025 Read Post »

Diagnostic Delays and Quality of Life in Japanese Patients with Pulmonary Hypertension: A Nationwide Survey, Pulmonary Therapy, March 18, 2025

A study published on March 18 2025 in Pulmonary Therapy provides a comprehensive view of pulmonary hypertension in Japan through a nationwide survey of 160 patients (119 with pulmonary arterial hypertension (PAH) and 41 with chronic thromboembolic pulmonary hypertension (CTEPH) and 211 physicians. We are particularly pleased to publish this article as one of the

Diagnostic Delays and Quality of Life in Japanese Patients with Pulmonary Hypertension: A Nationwide Survey, Pulmonary Therapy, March 18, 2025 Read Post »

Historical milestones and future horizons: exploring the diagnosis and treatment evolution of the pulmonary arterial hypertension in adults, Expert opinion on pharmacotherapy, March 19, 2025

This review, published on Expert Opinion on Pharmacotherapy on March 19, 2025, chronicles the evolution of pulmonary arterial hypertension (PAH) treatment from historical milestones to current challenges. Beginning with Ernst von Romberg’s first clinical description in 1891 and the advent of cardiac catheterization, pulmonary arterial hypertension diagnosis and treatment have advanced significantly in past decades.

Historical milestones and future horizons: exploring the diagnosis and treatment evolution of the pulmonary arterial hypertension in adults, Expert opinion on pharmacotherapy, March 19, 2025 Read Post »

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis, ESC Heart Failure, March 4, 2025

A recent study published in ESC Heart Failure (March 4, 2025) compared initial monotherapy versus combination therapy in pulmonary arterial hypertension (PAH) patients with cardiovascular comorbidities. Results showed that the combination therapy group experienced greater improvements in functional class, BNP/NT-proBNP levels, and overall risk status compared to monotherapy patients. However, no significant differences were observed

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis, ESC Heart Failure, March 4, 2025 Read Post »

“Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox”, International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025)

A recent analysis published in the International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025) examines the evolving landscape of pulmonary arterial hypertension (PAH). While traditionally viewed as primarily affecting young adult women without other health conditions, newer registry data from developed countries reveals a shift toward older patients with multiple co-morbidities like

“Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox”, International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025) Read Post »

Revisiting treatment of pulmonary arterial hypertension in the current era: A Greek scientific document, Hellenic Journal of Cardiology, February 19, 2025

The authors of the study “Revisiting treatment of pulmonary arterial hypertension in the current era: A Greek scientific document” published in the Hellenic Journal of Cardiology on February 19, 2025, presents a country-specific approach to care developed by a multidisciplinary team of cardiologists, pulmonologists, and intensivists. The authors discuss the advances in the field of

Revisiting treatment of pulmonary arterial hypertension in the current era: A Greek scientific document, Hellenic Journal of Cardiology, February 19, 2025 Read Post »

Miniature three dimensional arterial structures may allow proxy evaluation of human pulmonary artery contractility, British Journal of Pharmacology, February 20, 2025

The authors of a study titled “Engineered pulmonary artery tissues for measuring contractility, drug testing and disease modelling”, published in the British Journal of Pharmacology on Ferbruary 20, 2025, present an innovative technique to allow proxy evaluation of human pulmonary artery contractility. Vasoreactivity of the pulmonary arteries regulates blood flow through the lungs,they say, and

Miniature three dimensional arterial structures may allow proxy evaluation of human pulmonary artery contractility, British Journal of Pharmacology, February 20, 2025 Read Post »

The Aeson Total Artificial Heart helps three heart failure patients with pulmonary hypertension become heart transplant-eligible, The Journal of Heart and Lung Transplantation, February 5, 2025

Three heart failure patients with pulmonary hypertension (WHO Group II) became eligible for heart transplants after receiving the Aeson Total Artificial Heart, which effectively took place after 243, 155 and 109 days respectively. This innovative device, implanted with the help of the advanced Carmat system, replaces the heart’s ventricles and maintains continuous blood circulation, stabilizing

The Aeson Total Artificial Heart helps three heart failure patients with pulmonary hypertension become heart transplant-eligible, The Journal of Heart and Lung Transplantation, February 5, 2025 Read Post »

Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients, The Lancet, February 20, 2025

An article titled “Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients”, was published in The Lancet on February 20, 2025. It reports on discussions held between a group of international experts at the 20th Global CardioVascular Clinical Trialists Forum, CVCT (Washington DC, USA), patients’ representatives, and members

Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients, The Lancet, February 20, 2025 Read Post »

A proposal to involve people living with rare and complex conditions in the development of clinical practice guidelines, Patient Education and Counseling, February 19, 2025

The objective of the study published on February 19, 2025 as a Journal pre proof on Patient Edcuation and Counseling (§), is to develop a proposal to involve people living with rare and complex conditions in the development of clinical practice guidelines, based on a systematic review of qualitative literature (64 publications). The authors offer

A proposal to involve people living with rare and complex conditions in the development of clinical practice guidelines, Patient Education and Counseling, February 19, 2025 Read Post »

Medication Non-Adherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association (PHA) Registry (PHAR), Annals of the American Thoracic Society, February 18, 2025

Medication non-adherence in pulmonary arterial hypertension (PAH) can significantly impact patient outcomes, yet its prevalence and consequences remain understudied. This multi-center registry analysis examined self-reported non-adherence rates among pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (CTEPH) patients, identifying key socioeconomic predictors and associated healthcare outcomes. Using data from the Pulmonary Hypertension Association Registry (PHAR),

Medication Non-Adherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association (PHA) Registry (PHAR), Annals of the American Thoracic Society, February 18, 2025 Read Post »

The US Food and Drug Administration (FDA) has approved clinical trials to transplant organs from genetically modified pigs into people with kidney failure

The US Food and Drug Administration (FDA) has approved pioneering clinical trials by two biotech firms to evaluate the transplantation of kidneys from genetically engineered pigs into human patients with renal failure. This breakthrough authorization could mark a significant step toward addressing the chronic shortage of human organs for transplant. Until now, such transplants were

The US Food and Drug Administration (FDA) has approved clinical trials to transplant organs from genetically modified pigs into people with kidney failure Read Post »

Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies, European Respiratory Journal, January 30, 2025

This post-hoc, exploratory pooled analysis, published on January 30, 2025, on the European Respiratory Journal, combines data from the Phase 2 PULSAR and Phase 3 STELLAR studies on sotatercept, both international, multicentre, randomised, double-blind, placebo-controlled trials in pulmonary arterial hypertension patients. Out of 429 randomised patients, 237 received sotatercept and 192 placebo. After 24 weeks,

Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies, European Respiratory Journal, January 30, 2025 Read Post »

The Dutch Pulmonary Hypertension Association has contributed financially to the RECOMPENSE Phase 4 study on sotatercept conducted by the Amsterdam University Medical Center

The Dutch Pulmonary Hypertension Association, Stichting Pulmonale Hypertensie, has contributed financially with an amount of € 40.000 the RECOMPENSE – Right VEntricular COMPENsation with SotatercEpt – Phase 4 study conducted by the Amsterdam UMC. This research aims to investigate sotatercept’s effects on right ventricular function. Background Several large international studies have already been conducted in

The Dutch Pulmonary Hypertension Association has contributed financially to the RECOMPENSE Phase 4 study on sotatercept conducted by the Amsterdam University Medical Center Read Post »

TRANSLATE »
Scroll to Top